Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study)

BACKGROUND: Despite major improvements in the perioperative outcome of pancreas surgery, the prognosis of pancreatic cancer after curative resection remains poor. Adjuvant chemotherapy increases disease-free and overall survival, but this treatment cannot be offered to a significant proportion of pa...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Heinrich, Stefan, Pestalozzi, Bernhard, Lesurtel, Mickael, Berrevoet, Frederik, Laurent, Stéphanie, Delpero, Jean-Robert, Raoul, Jean-Luc, Bachellier, Phillippe, Dufour, Patrick, Moehler, Markus, Weber, Achim, Lang, Hauke, Rogiers, Xavier, Clavien, Pierre-Alain
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2011
Teme:
Study Protocol
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3176241/
https://ncbi.nlm.nih.gov/pubmed/21831266
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-11-346
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki